A weekly podcast exploring medicine 4.0 as we launch into the 21st Century of health. Join us as we highlight the science and investment case for the different diseases and conditions that life sciences companies are trying to diagnose and cure.
A weekly podcast exploring medicine 4.0 as we launch into the 21st Century of health. Join us as we highlight the science and investment case for the different diseases and conditions that life sciences companies are trying to diagnose and cure.
In some ways, cancer vaccines are a history of hype and hope, over success. But that hasn't stopped people from trying. In 2024, biotech CEOs are hoping that this time, it's different.
Research houses are predicting significant market growth come 2030, mRNA vaccines are making it through to phase three clinical trials for the first time, and there are exciting new discoveries in technologies that have already been tried and tossed on the rubbish pile.
So we asked two life sciences analysts about what they think of this market and whether this time, it really will be different. With Phase III regular Chris Kallos and Pitt Street Research cofounder Stuart Roberts.
Produced by Rachel Williamson and Charis Palmer. Music and effect credits to Ziso, Inspector J, Seth Parson and Boom Library.